Influence of zymosan (a non-specific macrophage stimulator) and of @entity3352 on liver tumours--an experimental study in XXXX .

@entity5 @entity19 @entity2918 @entity31156 @entity157 @entity35 @entity3352 @entity420
Zymosan--a non-specific macrophage-stimulating agent--reduces @entity5 take in the liver. The mechanism for this effect is not clear, but it may be mediated via the Kupffer cells and @entity2918 . On the other hand, the Prostaglandin-synthesis inhibitor, @entity3352 , inhibits @entity5 growth. Pretreatment with @entity31156 (3 mg 100 g-1) for 3 days of two different strains of @entity35 , inoculated in the liver with a @entity157 or an @entity420 cell suspension respectively, reduced @entity5 take and also initial @entity5 growth. The effect on @entity5 take and initial growth was inhibited by concomitant administration of @entity3352 (0.2 mg 100 g-1). When zymosan was administered after @entity5 cell inoculation the growth rate of the @entity157 was retarded, but this effect was not abrogated by @entity3352 . Pretreatment with @entity3352 had no significant effect on @entity5 take or initial growth. When given after the @entity5 was established in the liver, @entity3352 reduced the growth rate of the @entity157 , but not of the @entity420 . These results suggest that there are different mechanisms for the effects of zymosan on @entity5 take and on growth of an established @entity5 . In immunoincompetent @entity19 the effect on the @entity157 was similar to the effect in the @entity35 . In vitro both @entity5 were insensitive to zymosan and @entity3352 . This study confirms that pretreatment with a non-specific macrophage stimulator (zymosan) diminishes @entity5 take and growth in the liver, that the effect of zymosan on @entity5 take in the liver is abrogated by @entity3352 and that the zymosan effect on @entity5 take in the liver is at least partly mediated by the Kupffer cells and @entity2918 .
